EUVIMEDEUVIMED entdecken
Crossref

Rational design of a poly-L-glutamic acid-based combination conjugate for hormone-responsive breast cancer treatment

Paz Boix-Montesinos, María Medel, Alessio Malfanti, Snežana Đorđević, Esther Masiá, David Charbonnier, Paula Carrascosa-Marco, Ana Armiñán, María J Vicent

Journal of Controlled Release · 2024

DOI: 10.1016/j.jconrel.2024.09.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Paz Boix-Montesinos und 8 weiteren Autor:innen. Beteiligte Einrichtung: Polymer Therapeutics Lab., Príncipe Felipe Research Center, Av. Eduardo Primo Yúfera 3, 46012 Valencia, Spain. Hauptthemen laut MEDLINE: Polyglutamic Acid, Breast Neoplasms, Curcumin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 85 Literaturangaben. Gefördert von: European Research Council, España Ministerio de Ciencia Innovación y Universidades, CIBERONC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer represents the most prevalent tumor type worldwide, with hormone-responsive breast cancer the most common subtype. Despite the effectiveness of endocrine therapy, advanced disease forms represent an unmet clinical need. While drug combination therapies remain promising, differences in pharmacokinetic profiles result in suboptimal ratios of free drugs reaching tumors. We identified a synergistic combination of bisdemethoxycurcumin and exemestane through drug screening and rationally designed star-shaped poly-L-glutamic acid-based combination conjugates carrying these drugs conjugated through pH-responsive linkers for hormone-responsive breast cancer treatment. We synthesized/characterized single and combination conjugates with synergistic drug ratios/loadings. Physicochemical characterization/drug release kinetics studies suggested that lower drug loading prompted a less compact conjugate conformation that supported optimal release. Screening in monolayer and spheroid breast cancer cell cultures revealed that combination conjugates possessed enhanced cytotoxicity/synergism compared to physical mixtures of single-drug conjugates/free drugs; moreover, a combination conjugate with the lowest drug loading outperformed remaining conjugates. This candidate inhibited proliferation-associated signaling, reduced inflammatory chemokine/exosome levels, and promoted autophagy in spheroids; furthermore, it outperformed a physical mixture of single-drug conjugates/free drugs regarding cytotoxicity in patient-derived breast cancer organoids. Our findings highlight the importance of rational design and advanced in vitro models for the selection of polypeptide-based combination conjugates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyglutamic AcidBreast NeoplasmsCurcuminHumansFemaleDrug LiberationCell Line, TumorDiarylheptanoidsDrug DesignDrug SynergismAntineoplastic Combined Chemotherapy ProtocolsMCF-7 CellsAntineoplastic AgentsAndrostadienes

Stichwörter der Autor:innen

Breast cancerCancer spheroidsCombination therapyPatient-derived organoidsPoly-L-glutamic acidPolypeptide-based combination conjugates

Substanzen

Polyglutamic AcidCurcuminexemestaneDiarylheptanoidsAntineoplastic AgentsAndrostadienes

Autor:innen und Institutionen

  • Polymer Therapeutics Lab., Príncipe Felipe Research Center, Av. Eduardo Primo Yúfera 3, 46012 Valencia, Spain.
  • Polymer Therapeutics Lab., Príncipe Felipe Research Center, Av. Eduardo Primo Yúfera 3, 46012 Valencia, Spain; Centro de Investigación Biomédica en Red en Cancer, (CIBERONC), Instituto de Salud Carlos III, Spain.
  • Polymer Therapeutics Lab., Príncipe Felipe Research Center, Av. Eduardo Primo Yúfera 3, 46012 Valencia, Spain; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Pad…
  • Polymer Therapeutics Lab., Príncipe Felipe Research Center, Av. Eduardo Primo Yúfera 3, 46012 Valencia, Spain; Centro de Investigación Biomédica en Red en Cancer, (CIBERONC), Instituto de Salud Carlos III, Spain; Screen…
  • Polymer Therapeutics Lab., Príncipe Felipe Research Center, Av. Eduardo Primo Yúfera 3, 46012 Valencia, Spain; Screening Platform, Príncipe Felipe Research Center, Av. Eduardo Primo Yúfera 3, 46012 Valencia, Spain; Cent…
  • Polymer Therapeutics Lab., Príncipe Felipe Research Center, Av. Eduardo Primo Yúfera 3, 46012 Valencia, Spain; Centro de Investigación Biomédica en Red en Cancer, (CIBERONC), Instituto de Salud Carlos III, Spain. Electr…

Förderung

  • European Research Council
  • España Ministerio de Ciencia Innovación y Universidades
  • CIBERONC
  • Federación Española de Enfermedades Raras
  • Generalitat Valenciana

Zitieren

APA

Boix-Montesinos, P., Medel, M., Malfanti, A., Đorđević, S., Masiá, E., Charbonnier, D., Carrascosa-Marco, P., Armiñán, A., & Vicent, M. J. (2024). Rational design of a poly-L-glutamic acid-based combination conjugate for hormone-responsive breast cancer treatment. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.09.002

Vancouver

Boix-Montesinos P, Medel M, Malfanti A, Đorđević S, Masiá E, Charbonnier D, et al. Rational design of a poly-L-glutamic acid-based combination conjugate for hormone-responsive breast cancer treatment. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.09.002

BibTeX
@article{BoixMontesinos2024,
  author = {Boix-Montesinos, Paz and Medel, María and Malfanti, Alessio and Đorđević, Snežana and Masiá, Esther and Charbonnier, David and Carrascosa-Marco, Paula and Armiñán, Ana and Vicent, María J},
  title = {Rational design of a poly-L-glutamic acid-based combination conjugate for hormone-responsive breast cancer treatment},
  journal = {Journal of Controlled Release},
  year = {2024},
  doi = {10.1016/j.jconrel.2024.09.002}
}
Kostenlos starten →